Karo Healthcare will soon have new private-equity owners after EQT agreed a deal to sell the Stockholm, Sweden-based consumer health player to KKR. While financial details were not disclosed, the transaction values Karo at more than €2.5bn ($2.8bn), according to media reports.
With distribution in more than 90 countries, and claiming “top brand positions” across European markets, Karo’s portfolio spans consumer health categories including skin and intimate health, dietary supplements, digestive health and foot health
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?